{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:35:16Z","timestamp":1767170116042,"version":"build-2238731810"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2020,7,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p xml:lang=\"en\">Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID\u201019). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug interactions with emerging COVID\u201019 treatments. Common unintended nontherapeutic target effects of COVID\u201019 treatment include potassium channel blockade, cytochrome P 450 isoenzyme inhibition or activation, and P\u2010glycoprotein inhibition. Drug\u2010drug interactions with antiarrhythmic drugs and anticoagulants in these patients may lead to significant bradycardia, ventricular arrhythmias, or severe bleeding. It is important for clinicians to be aware of these interactions, drug metabolism changes, and clinical consequences when choosing antiarrhythmic drugs and anticoagulants for COVID\u201019 patients with atrial fibrillation. The objective of this review is to provide a practical guide for clinicians who are managing COVID\u201019 patients with concomitant atrial fibrillation.<\/jats:p>","DOI":"10.1161\/jaha.120.017529","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T05:09:52Z","timestamp":1591679392000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Guidance on Short\u2010Term Management of Atrial Fibrillation in Coronavirus Disease 2019"],"prefix":"10.1161","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9419-5854","authenticated-orcid":false,"given":"Pattara","family":"Rattanawong","sequence":"first","affiliation":[{"name":"Division of Heart Rhythm Services Department of Cardiovascular Diseases Mayo Clinic Arizona Phoenix AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Win","family":"Shen","sequence":"additional","affiliation":[{"name":"Division of Heart Rhythm Services Department of Cardiovascular Diseases Mayo Clinic Arizona Phoenix AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-2862","authenticated-orcid":false,"given":"Hicham","family":"El Masry","sequence":"additional","affiliation":[{"name":"Division of Heart Rhythm Services Department of Cardiovascular Diseases Mayo Clinic Arizona Phoenix AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1976-6420","authenticated-orcid":false,"given":"Dan","family":"Sorajja","sequence":"additional","affiliation":[{"name":"Division of Heart Rhythm Services Department of Cardiovascular Diseases Mayo Clinic Arizona Phoenix AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-0243","authenticated-orcid":false,"given":"Komandoor","family":"Srivathsan","sequence":"additional","affiliation":[{"name":"Division of Heart Rhythm Services Department of Cardiovascular Diseases Mayo Clinic Arizona Phoenix AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-6744","authenticated-orcid":false,"given":"Arturo","family":"Valverde","sequence":"additional","affiliation":[{"name":"Division of Heart Rhythm Services Department of Cardiovascular Diseases Mayo Clinic Arizona Phoenix AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-1062","authenticated-orcid":false,"given":"Luis R.","family":"Scott","sequence":"additional","affiliation":[{"name":"Division of Heart Rhythm Services Department of Cardiovascular Diseases Mayo Clinic Arizona Phoenix AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.04.001"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.031"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.03.040"},{"key":"e_1_3_1_7_2","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID\u201019): a review 2020","volume":"323","author":"Sanders JM","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID\u201019): a review 2020. JAMA. 2020;323:1824\u20131836.","journal-title":"JAMA"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.03.024"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1585"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2010419"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa388"},{"key":"e_1_3_1_12_2","article-title":"Covid\u201019 cases in a no\u2010Covid\u201019 geriatric acute care setting: a sporadic occurrence?","author":"Fumagalli S","unstructured":"Fumagalli S, Salani B, Gabbani L, Mossello E, Ungar A. Covid\u201019 cases in a no\u2010Covid\u201019 geriatric acute care setting: a sporadic occurrence? Eur J Intern Med. In press. ISSN 0953\u20106205, https:\/\/doi.org\/10.1016\/j.ejim.2020.04.058.","journal-title":"Eur J Intern Med"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.0950"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05991-x"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23088"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S10095"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.022"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa114"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x"},{"key":"e_1_3_1_22_2","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID\u201019: results of an open\u2010label non\u2010randomized clinical trial","author":"Gautret P","unstructured":"Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, et al. Hydroxychloroquine and azithromycin as a treatment of COVID\u201019: results of an open\u2010label non\u2010randomized clinical trial. Int J Antimicrob Agents. In press. ISSN 0924\u20108579, https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949.","journal-title":"Int J Antimicrob Agents"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00095809"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-017-9401-7"},{"key":"e_1_3_1_25_2","unstructured":"U.S. Food and Drug Administration . KALETRA safely and effectively. November 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021251s052_021906s046lbl.pdf\/. Accessed April 19 2020."},{"key":"e_1_3_1_26_2","unstructured":"European Medicine Agency . Remdesivir Gilead. April 2020. https:\/\/www.ema.europa.eu\/en\/documents\/other\/summary\u2010compassionate\u2010use\u2010remdesivir\u2010gilead_en.pdf. Accessed April 19 2020."},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-005-5455-y"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A181"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1844"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02282-12"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199019050-00003"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2423-3"},{"key":"e_1_3_1_33_2","unstructured":"U.S. Food and Drug Administration . ESBRIET\u00ae (pirfenidone) capsules and film\u2010coated tablets for oral use. January 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208780s000lbl.pdf\/. Accessed April 19 2020."},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1024110"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100340"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12284"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098613481023"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016627"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.019927"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199302000-00019"},{"key":"e_1_3_1_41_2","first-page":"31","article-title":"In vitro metabolism of quinidine: the (3S)\u20103\u2010hydroxylation of quinidine is a specific marker reaction for cytochrome P\u20104503A4 activity in human liver microsomes","volume":"289","author":"Nielsen TL","year":"1999","unstructured":"Nielsen TL, Rasmussen BB, Flinois JP, Beaune P, Brosen K. In vitro metabolism of quinidine: the (3S)\u20103\u2010hydroxylation of quinidine is a specific marker reaction for cytochrome P\u20104503A4 activity in human liver microsomes. J Pharmacol Exp Ther. 1999;289:31\u201337.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198003133021106"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199710000-00007"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746120-00002"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1403"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283588fe5"},{"key":"e_1_3_1_47_2","unstructured":"Lang JP. Brigham and Women's Hospital COVID\u201019 clinical guidelines. April 2020. https:\/\/covidprotocols.org. Accessed April 11 2020."},{"key":"e_1_3_1_48_2","unstructured":"U.S. Food and Drug Administration . NORVIR safely and effectively. June 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209512lbl.pdf\/. Accessed April 19 2020."},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00197.x"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31258-2"},{"key":"e_1_3_1_51_2","volume-title":"Selective Beta\u20101\u2010Blockers. StatPearls","author":"Tucker WD","year":"2020","unstructured":"Tucker WD, Theetha Kariyanna P. Selective Beta\u20101\u2010Blockers. StatPearls. Treasure Island, FL: StatPearls Publishing; 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430685\/."},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.06.052"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct065916"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2010.01.008"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.1.51"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800456"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.19.2385"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03402-4"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.7.1613"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.5455\/2319-2003.ijbcp20140244"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky139"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.02.008"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14817"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225297"},{"key":"e_1_3_1_65_2","unstructured":"U.S. Food and Drug Administration . XARELTO\u00ae (rivaroxaban) safely and effectively. Revised December 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202439s001lbl.pdf\/. Accessed April 19 2020."},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306638"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0261-1"},{"key":"e_1_3_1_68_2","unstructured":"U.S. Food and Drug Administration . PRADAXA\u00ae (dabigatran etexilate mesylate) safely and effectively. November 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022512s007lbl.pdf\/. Accessed April 19 2020."},{"key":"e_1_3_1_69_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.13.1055.35026"},{"key":"e_1_3_1_70_2","doi-asserted-by":"publisher","DOI":"10.1177\/0897190018758541"},{"key":"e_1_3_1_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000530"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80017-4"}],"updated-by":[{"DOI":"10.1161\/jaha.119.014579","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000}}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.120.017529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:45:11Z","timestamp":1715586311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.120.017529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":71,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,7,21]]}},"alternative-id":["10.1161\/JAHA.120.017529"],"URL":"https:\/\/doi.org\/10.1161\/jaha.120.017529","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"2020-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e017529"}}